Numab Therapeutics AG
- Country
- 🇨🇭Switzerland
- Ownership
- Holding
- Established
- 2011-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.numab.com
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
- Conditions
- Triple Negative Breast CancerOvarian CarcinomaLeiomyosarcomaAdenocarcinoma - Gastroesophageal Junction (GEJ)Endometrial CancerPeritoneal CarcinomaMesothelioma, MalignantAdenocarcinoma of the StomachMelanoma, MalignantRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Numab Therapeutics AG
- Target Recruit Count
- 11
- Registration Number
- NCT06299163
- Locations
- 🇺🇸
The University of Chicago Medical Center (UCMC), Chicago, Illinois, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)
- First Posted Date
- 2023-05-16
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Yellow Jersey Therapeutics AG
- Target Recruit Count
- 126
- Registration Number
- NCT05859724
- Locations
- 🇺🇸
First OC Dermatology Research, Fountain Valley, California, United States
🇺🇸California Clinical Trials Medical Group (CCTMG) managed by Parexel, Glendale, California, United States
🇺🇸TCR Medical Corporation, San Diego, California, United States
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
- Conditions
- Ovarian CarcinomaHead and Neck Squamous Cell CarcinomaTriple Negative Breast CancerAdvanced Solid TumorColorectal CancerFallopian Tube CancerNon-small Cell Lung CancerSquamous Cell CarcinomaPeritoneal Carcinoma
- Interventions
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Numab Therapeutics AG
- Target Recruit Count
- 52
- Registration Number
- NCT04442126
- Locations
- 🇺🇸
UCHealth Poudre Valley Hospital, Fort Collins, Colorado, United States
🇺🇸Augusta University Medical Center, Augusta, Georgia, United States
🇺🇸Tulane University Medical Center, New Orleans, Louisiana, United States